Netupitant
- Generic Name
- Netupitant
- Brand Names
- Akynzeo
- Drug Type
- Small Molecule
- Chemical Formula
- C30H32F6N4O
- CAS Number
- 290297-26-6
- Unique Ingredient Identifier
- 7732P08TIR
- Background
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn The...
- Indication
用于治疗和预防化疗引起的急性和延迟性恶心、呕吐。
- Associated Conditions
- Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Instituto Brasileiro de Controle do Cancer
- Target Recruit Count
- 50
- Registration Number
- NCT04669132
- Locations
- 🇧🇷
IBCC Oncologia, São Paulo, Brazil
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 67
- Registration Number
- NCT03204279
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇷🇺Chelyabinsk Regional Children's Clinical Hospital, Chelyabinsk, Russian Federation
🇺🇦National Institute of Cancer, Research Department of Pediatric Oncology, Kyiv, Ukraine
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT03097588
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT03040726
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.